EUVIMEDEUVIMED entdecken
Klinische Studie (Phase IV)ÄquivalenzstudieMultizentrische StudieOpen Access

Long-Term Anticoagulation Discontinuation After Catheter Ablation for Atrial Fibrillation

Daehoon Kim, Jaemin Shim, Eue-Keun Choi, Il-Young Oh, Jun Kim, Young Soo Lee, Junbeom Park, Jum-Suk Ko, Kyoung-Min Park, Jung-Hoon Sung, Hyung Wook Park, Hyung-Seob Park und 12 weitere

JAMA · 14.10.2025 · 334 (14) · 1246

DOI: 10.1001/jama.2025.14679 ↗

Kurz gefasst

Klinische Studie (Phase IV) in der Zeitschrift JAMA, erschienen am 14.10.2025. Verfasst von Daehoon Kim und 23 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea. Hauptthemen laut MEDLINE: Anticoagulants, Atrial Fibrillation, Catheter Ablation, Postoperative Complications. Die Arbeit wurde bisher 120-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Data from randomized clinical trials on a long-term anticoagulation strategy for patients after catheter-based ablation for atrial fibrillation (AF) are lacking.

Objective

To evaluate whether discontinuing oral anticoagulant therapy provides superior clinical outcomes compared with continuing oral anticoagulant therapy in patients without documented atrial arrhythmia recurrence after catheter ablation for AF. Design, Setting, and Participants A randomized clinical trial including 840 adult patients (aged 19-80 years) who were enrolled and randomized from July 28, 2020, to March 9, 2023, at 18 hospitals in South Korea. Enrolled patients had at least 1 non–sex-related stroke risk factor (determined using the CHA 2 DS 2 -VASc score [range, 0-9]) and no documented recurrence of atrial arrhythmia for at least 1 year after catheter ablation for AF. The CHA 2 DS 2 -VASc score is used as an assessment of stroke risk among patients with AF (calculated using point values for congestive heart failure, hypertension, ≥75 years of age, diabetes, stroke or transient ischemic attack, vascular disease, between 65 and 74 years of age, and sex category). The date of final follow-up was June 4, 2025.

Interventions

The patients were randomly assigned in a 1:1 ratio to discontinue oral anticoagulant therapy (n = 417) or continue oral anticoagulant therapy (with direct oral anticoagulants; n = 423). Main Outcomes and Measures The primary outcome was the first occurrence of a composite of stroke, systemic embolism, and major bleeding at 2 years. Individual components of the primary outcome (such as ischemic stroke and major bleeding) were assessed as secondary outcomes.

Results

Of the 840 adults randomized, the mean age was 64 (SD, 8) years, 24.9% were women, the mean CHA 2 DS 2 -VASc score was 2.1 (SD, 1.0), and 67.6% had paroxysmal AF. At 2 years, the primary outcome occurred in 1 patient (0.3%) in the discontinue oral anticoagulant therapy group vs 8 patients (2.2%) in the continue oral anticoagulant therapy group (absolute difference, –1.9 percentage points [95% CI, −3.5 to −0.3]; P = .02). The 2-year cumulative incidence of ischemic stroke was 0.3% in the discontinue oral anticoagulant therapy group vs 0.8% in the continue oral anticoagulant therapy group (absolute difference, −0.5 percentage points [95% CI, −1.6 to 0.6]). Major bleeding occurred in 0 patients in the discontinue oral anticoagulant therapy group vs 5 patients (1.4%) in the continue oral anticoagulant therapy group (absolute difference, –1.4 percentage points [95% CI, −2.6 to −0.2]). Conclusions and Relevance Among patients without documented atrial arrhythmia recurrence after catheter ablation for AF, discontinuing oral anticoagulant therapy resulted in a lower risk for the composite outcome of stroke, systemic embolism, and major bleeding vs continuing direct oral anticoagulant therapy. Trial Registration ClinicalTrials.gov Identifier: NCT04432220

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnticoagulantsAtrial FibrillationCatheter AblationPostoperative ComplicationsWithholding TreatmentAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedYoung AdultAdministration, OralHemorrhageProspective StudiesRecurrenceRisk FactorsStrokeThromboembolismTreatment Outcome

Substanzen

Anticoagulants

Autor:innen und Institutionen

  • Division of Cardiology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea.
  • Department of Cardiology, Korea University Hospital, Seoul, South Korea.
  • Department of Internal Medicine, Seoul National University College of Medicine and Seoul National University Hospital, Seoul, South Korea.
  • Department of Cardiology, Seoul National University Bundang Hospital, Seongnam, South Korea.
  • Heart Institute, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea.
  • Division of Cardiology, Daegu Catholic University Hospital, Daegu, South Korea.

Zitieren

APA

Kim, D., Shim, J., Choi, E. K., Oh, I. Y., Kim, J., Lee, Y. S., Park, J., Ko, J. S., Park, K. M., Sung, J. H., Park, H. W., Park, H. S., Kim, J. Y., Kang, K. W., Kim, D., Park, J. K., Kim, D. H., Kim, J. B., Yu, H. T., …, & ALONE-AF Investigators (2025). Long-Term Anticoagulation Discontinuation After Catheter Ablation for Atrial Fibrillation. JAMA, 334(14), 1246. https://doi.org/10.1001/jama.2025.14679

Vancouver

Kim D, Shim J, Choi EK, Oh IY, Kim J, Lee YS, et al. Long-Term Anticoagulation Discontinuation After Catheter Ablation for Atrial Fibrillation. JAMA. 2025;334(14):1246. doi:10.1001/jama.2025.14679

BibTeX
@article{Kim2025,
  author = {Kim, Daehoon and Shim, Jaemin and Choi, Eue-Keun and Oh, Il-Young and Kim, Jun and Lee, Young Soo and Park, Junbeom and Ko, Jum-Suk and Park, Kyoung-Min and Sung, Jung-Hoon and Park, Hyung Wook and Park, Hyung-Seob and Kim, Jong-Youn and Kang, Ki-Woon and Kim, Dongmin and Park, Jin-Kyu and Kim, Dae-Hyeok and Kim, Jin-Bae and Yu, Hee Tae and Kim, Tae-Hoon and Uhm, Jae-Sun and Pak, Hui-Nam and Joung, Boyoung and ALONE-AF Investigators, ALONE-AF Investigators},
  title = {Long-Term Anticoagulation Discontinuation After Catheter Ablation for Atrial Fibrillation},
  journal = {JAMA},
  year = {2025},
  volume = {334},
  number = {14},
  pages = {1246},
  doi = {10.1001/jama.2025.14679}
}
Kostenlos starten →